依达拉奉注射液在颅脑外伤治疗作用中的临床研究被引量：1

Clinical study in the treatment of craniocerebral injury with edaravone

下载PDF

导出

摘要目的探讨依达拉奉注射液在颅脑外伤中的治疗作用。方法将50例颅脑外伤患者随机分为两组,治疗组在对照组常规治疗的基础上加用依达拉奉注射液30mg,每日2次,连用21天;两组分别于治疗前及治疗后21天进行神经功能缺损程度评分与疗效评定。结果治疗21天后,治疗组神经功能缺损评分为(9.6±6.3)分,低于对照组的(14.4±7.6)分(P<0.05),治疗组的显效率和总有效率分别为44.0%和68.0%,高于对照组的32.0%和52.0%(P<0.05)。结论依达拉奉治疗颅脑损伤疗效确切,有重要的临床应用价值。 Objective To evaluate the clinical effect of edaravone in the treatment of craniocerebral injury. Methods 50 paitents were randomly divided into 2 groups. The control group reeived routine therapy. Besides the same therapy, the treated group was given with edaravone 30rag biw day for 21 days. Necurological functional deficit scores and the efficacy were assessed. Results After 21 days the treated group＇s scores （9,6±6.3） was lower than the control group scores （14.4±7.6）（P〈0.05）. There was also difference between the two groups in apparent effect rate and inprovement rate （P〈0.05）. Conclusions Edarovone is an effective in the treatment of cranioncerebral injury.

作者胡蓉盛宇伟孟庆浩

机构地区上海交通大学附属上海市第一人民医院宝山分院

出处《海南医学》 CAS 2006年第10期20-21,共2页 Hainan Medical Journal

关键词颅脑外伤依达拉奉随机临床试验(RCT) Cranioncerebral injury Edaravone Randomized clinical trial （RCT）

分类号 R651.15 [医药卫生—外科学]

引文网络
相关文献

参考文献5

1吴在德.外科学[M](第五版)[M].北京:人民卫生出版社,2000.578.
2杨政,吴玉林.治疗急性脑梗死的新型脑保护药依达拉奉[J].中国新药杂志,2002,11(12):911-913. 被引量：353
3[美]Sabiston,D.C 主编.王德炳主译.克氏外科学[M].第十五版.北京:人民卫生出版社,2000,1160-1161.
4Kennedy T.Effects of edaravone on human neutrophil funtction[J].Acta Anaesthesiol Scand,2005,49(3):385-386.
5Uchida K and Sekino H.A study of free radical reactions in experimental brain injury in rats[J].St.Msrianna Med,2001,29:375-382.

二级参考文献11

1横田慎一熊毅雄治内海光朝.A Pharmacokinetic Study of MCI—186,a novel drug for cerebrovascular disease in elderly and young healthy subjects[J].临床药理,1997,28(3):693-702.
2Mizuno A,Umemura K,Nakashima M.Inhibitory effect MCI-186,a free radical scavenger,on cerebral ischemia following rat middle cerebral artery occlusion[J].Gen Pharmacol,1998,30(4)∶575-578.
3Kawai H,Nakai H,Misao S,et al.Effects of a novel free radical scavenger,MCI-186,on ischemic brain damage in the rat distal middle cerebral artery occlusion model[J].J Pharmacol Exp Ther,1997,281(2)∶921-927.
4Tabrizchi R.Edaravone Mitsubishi-Tokyo[J].Curr Opin Investig Drugs,2000,1(3)∶347-454.
5Yamamoto T,Yuki S,Watanabe T,et al.Delayed neuronal death prevented by inhibition of increased hydroxyl radical formation in a transient cerebral ischemia[J].Brain Res,1997,762(12)∶240-242.
6Watanabe T,Egawa M.Effects of an antistroke agent MCI-186 on cerebral arachidonate cascades[J].J Pharmacol Exp Ther,1994,271(3)∶1624-1629.
7Watanabe T,Morita I,Nishi H,et al.Preventive effect of MCI-186 on 15-HPETE induced vascular endothelial cell injury in vitro[J].Prostaglandins Leukotrienes Essent Fatty Acids,1998,33(1)∶81-87.
8Mitsumori K,Sakuragi M,Kitami K,et al.The effect MCI-186 on regional cerebral blood flow in patients with acute cerebral infarction-A sequential SPECT study[J].Ther Res,1998,19(4)∶1333-1345.
9山本美奈子高松康雄.Pharmacokinetic studies of 3—methyl—1—phenyl—2—pyrazolin—5—one（MCI—186）：protein binding and distribution to red blood cell[J].药理と治疗,1997,25(17):1755-1763.
10大友英一东仪英夫小暮久也.MCI—186の脑梗死急性期に对する效果[J].Ther Res,1998,19(4):1311-1332.